Clearview Limited has announced that it has purchased BioMachines on Dec. 29, 2005. Sam Tetlow, founding partner of Clearview and a principal with Research Triangle Ventures, is now chairman of BioMachines.
He has named Tom Larrichio, formerly vice president of business development at TriVirix International, Inc., as BioMachines' chief executive officer.
"After a comprehensive review of the genomic and proteomics industry, we believe BioMachines is uniquely positioned to achieve excellent commercial results from its market-proven, proprietary products," said Tetlow.
"The company has deep scientific expertise and a pipeline of novel diagnostic tools that will have a meaningful impact to the work of leading drug discovery researchers, especially those working in the growing field of proteomics."
Tetlow said he selected Larrichio as BioMachines' new CEO because of his sales acumen, extensive management experience and life science knowledge.
He adds, "Tom has the requisite commercial expertise to take the company to the next level."